Roche records research success with flu drug Xofluza
Published: Thursday, Sep 19th 2024, 08:00
Retour au fil d'actualité
Roche has achieved a research success with its drug Xofluza in the treatment of influenza. As the latest data from the pivotal Centerstone study show, Xofluza has reduced the transmission of influenza from an infected person to household members.
This is the first time that an antivirus used to treat a respiratory viral disease has shown a benefit in reducing transmission, according to a press release issued by the pharmaceutical company on Thursday.
Reducing the spread of infection in the home could help to limit transmission within communities and societies, thereby reducing the burden of seasonal and pandemic influenza on healthcare systems, the company adds.
As the data show, even a single dose of Xofluza was enough to significantly reduce the likelihood of other people in their household catching the virus.
According to Roche, these new data could further strengthen the benefits of Xofluza, which is currently approved for the treatment of symptoms and prevention of infection following exposure to the virus. The initial results will be presented at the Options XII for the Control of Influenza 2024 congress in Australia at the end of September.
©Keystone/SDA
French 
English 
German 
Spanish 
Arabic